Ireland
--:--IST
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lisbon
Clinical trial register · Portugal

Clinical Trials in Lisbon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Portugal and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1100 matching records held by the registry are in this view. Synced 03 Oct 2026, 03:16 UTC
1100
Studies in scope
all four open statuses
535
Recruiting now
open to new participants
284
Lead sponsors
across recruiting studies
Top sites
Lisbon 33 Porto 26 Braga 9 Loures 8 Vila Nova de Gaia 7
Narrow the registerReset
Recruitment status
Phase
Site location
Lisbon33 Porto26 Braga9 Loures8 Vila Nova de Gaia7
All 14 locations
Target enrolment
to

Trials with a site in Lisbon

33 of 1100 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Portugal
Start
Recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
AstraZeneca
Phase 3
1,072
Braga, Lisbon, Porto
2026-08-31
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
Guimarães, Lisbon
2026-07-08
Recruiting
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT07402915Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal
AstraZeneca
Phase 1
32
Lisbon
2026-01-26
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
AstraZeneca
Phase 3
830
Alcabideche, Braga, Coimbra, Lisbon, Loures, Matosinhos Municipality, Porto
2025-04-10
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
AstraZeneca
Phase 2
194
Lisbon, Porto
2024-08-27
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Braga, Lisbon, Porto
2024-06-29
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
AstraZeneca
Phase 3
100
Lisbon, Porto
2024-03-14
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Vila Real, Faro, Lisbon
2023-12-20
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
5,511
Amadora, Braga, Lisbon, Porto, Vila Nova de Gaia, Vila Real
2023-10-05
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934ATTR Amyloidosis
AstraZeneca
Observational
52,121
Lisbon, Porto
2023-08-21
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Amadora, Braga, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2023-03-31
Active, closed
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
NCT05267613Erosive Esophagitis
DrugNexium
AstraZeneca
Phase 3
53
Coimbra, Lisbon, Porto, Viana do Castelo
2022-07-01
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Lisbon, Porto
2022-05-23
Recruiting
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550Non-small Cell Lung Cancer
AstraZeneca
Phase 2
630
Lisbon, Porto
2022-04-14
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
AstraZeneca
Phase 3
760
Lisbon, Vila Real
2022-03-28
Active, closed
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
315
Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2021-06-30
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
1,371
Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2021-01-28
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963Ovarian Cancer, Breast Cancer
AstraZeneca
Phase 3
185
Lisbon, Porto
2020-08-04
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
AstraZeneca
Phase 3
923
Lisbon, Porto
2019-06-25
Active, closed
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847Metastatic Triple Negative Breast Cancer
AstraZeneca
Phase 2
273
Lisbon, Loures, Porto, Vila Nova de Gaia
2018-03-07
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
AstraZeneca
Phase 3
953
Amadora, Lisbon, Porto
2015-11-03
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
AstraZeneca
Phase 3
1,126
Lisbon, Loures, Porto
2015-11-02
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
AstraZeneca
Phase 3
1,837
Lisbon, Loures, Porto
2014-04-22
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
AstraZeneca
Phase 3
510
Amadora, Coimbra, Lisbon, Porto, Vila Nova de Gaia
2013-09-25
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Portuguese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 October 2026. https://priyalifescience.com/clinical-trials-portugal/city/lisbon

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Portugal and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,100 studies in total at the last sync on 03 Oct 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies with a site in Lisbon that also match the filters currently applied.

How many clinical trials are recruiting in Lisbon?

12 of the 33 studies on this page are recruiting new participants as of the 03 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 21 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lisbon), 33 studies
PhaseStudiesRecruitingShare
Phase 322666.7%
Phase 26218.2%
Observational4312.1%
Phase 1113%

Most active sponsors

Lead sponsors with the most studies (Lisbon)
Lead sponsorStudiesRecruiting
AstraZeneca3312
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.